05:34 PM EDT, 03/23/2026 (MT Newswires) -- Aardvark Therapeutics ( AARD ) filed a shelf registration statement on Monday with the US Securities and Exchange Commission for the potential sale of up to $400 million in securities.

The filing covers common and preferred stock, debt securities, warrants, rights, units, and depositary shares.

Net proceeds will be used for general corporate purposes.